Year: 2014
Physiologically-based IVIVC at a Population Level—Deconvoluting In Vivo Dissolution and Identifying Sources of Variability
Population Pharmacokinetics Analysis of Vigabatrin in Adults and Children with Epilepsy and Children with Infantile Spasms
Vigabatrin is an inhibitor of γ-aminobutyric acid transaminase. The purpose of these analyses was to develop a population pharmacokinetics model to characterize the vigabatrin concentration–time profile for adults and children with refractory complex partial seizures (rCPS) and for children with infantile spasms (IS); to identify covariates that affect its disposition, and to enable predictions of … Continued
Certara Consultants to Present PK/PD Modeling Advances at the AAPS Annual Meeting and Exposition
Certara will participate in 10 seminars and forums, launch the new version of its Phoenix PK/PD software platform, and support the National Organization for Rare Disorders during the show. PRINCETON, NJ – Oct. 31, 2014 – Certara®, the leading global technology-enabled drug development and drug safety consultancy, today announced that its Simcyp® and Pharsight® consultants … Continued
Certara Receives FDA Grant to Enhance Simcyp Simulator’s Mechanistic Dermal Absorption Model
Enhanced solution will be able to model additional populations, and diseases, and also consider new mechanisms that impact dermal absorption. ST. LOUIS, MO – Oct. 23, 2014 – Certara®, the leading global technology-enabled drug development and drug safety consultancy, today announced that it has received a Food and Drug Administration (FDA) Office of Generic Drugs … Continued
